This open-label, inpatient pilot study is to assess the safety of lofexidine(1.6 2.4, and 4.0 mg per day) in the treatment of opiate- dependent individuals under-going medically-supervised opiate withdrawal. A secondary goal of the study is to provide preliminary evidence for the potential of lofexidine 2.4 mg per day, to reduce both the signs and symptoms opiate withdrawal.
Showing the most recent 10 out of 1085 publications